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A water-soluble polysaccharide (BIWS-4b) was puriﬁed from the fruit bodies of Bulgaria inquinans (Fries). It is composed of
mannose (27.2%), glucose (15.5%) and galactose (57.3%). Its molecular weight was estimated to be 7.4kDa (polydispersity index,
Mw/Mn:1.35).StructuralanalysesindicatedthatBIWS-4bmainlycontains(1 → 6)-linked,(1 → 5)-linkedand(1 → 5,6)-linked
β-Galf units; (1 → 4)-linked and non-reducing terminal β-Glcp units; and (1 → 2)-linked, (1 → 6)-linked, (1 → 2,6)-linked
and non-reducing terminal α-Manp units. When examined by the 4-day method and in a prophylactic assay in mice, BIWS-4b
exhibited markedly suppressive activity against malaria while enhancing the activity of artesunate. Immunological tests indicated
that BIWS-4b signiﬁcantly enhanced macrophage phagocytosis and splenic lymphocyte proliferation in malaria-bearing mice and
normal mice. The anti-malarial activity of BIWS-4b might be intermediated by enhancing immune competence and restoring
artesunate-suppressed immune function. Thus, BIWS-4b is a potential adjuvant of anti-malaria drugs.
1.Introduction
Many fungi are used as traditional medicines in the
treatment of various human diseases such as hepatitis,
hypertension,hypercholesterolemiaandgastriccancer[1–4].
Recently, fungal polysaccharides have received considerable
attention as an important class of bioactive substances
because of their potent biological and pharmacological
activities, especially immunological and antitumor activities
[5–8]. Discovery and evaluation of new bioactive polysac-
charides from medicinal fungi has emerged as one of the
hot research ﬁelds in chemistry and biology. Due to their
immunological activities, some fungal polysaccharides could
protect hosts from microbes and parasites such as malaria
[9].
The non-lichenized ascomycete Bulgaria inquinans
(Fries) is an edible wood-inhabiting ascomycete that grows
on freshly felled oak and commonly found in the Changbai
Mountain area of China. It has been used as food and
folk antitumor medicine for a long time. Several small
molecule compounds isolated from the fruit bodies of B.
inquinans (Fries) have been found to have antitumor [10],
antipruritic and antierythema activities [11]. However, the
polysaccharides from B. inquinans (Fries) have not been
thoroughly studied. In a previous study, we fractionated
polysaccharides from B. inquinans (Fries) and a low molec-
ular weight β-(1→6)-d-glucan was characterized [12]. In
the present article, we describe the characterization of the
more complex heteropolysaccharide fraction BIWS-4b from
B. inquinans (Fries) and its anti-malarial activity in vivo as
well as a possible mechanism of action.
2. Methods
2.1. Materials and Chemicals. Fruit bodies of B. inquinans
(Fries) were collected from Changbai Mountain, China and
identiﬁed by Professor Hongxing Xiao at Northeast Normal
University in Changchun, China. A voucher specimen (No.
20070802) was deposited at the School of Life Sciences,
Northeast Normal University.
Artesunate was purchased from Guilin Pharmaceutical
Co., Ltd., China. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphen-
yltetrazolium bromide (MTT), concanavalin A (ConA),
lipopolysaccharide (LPS), Sepharose CL-6B and Sephadex
G-75 were purchased from Sigma Chemical Co. RPMI-
1640 medium was obtained from Gibco Invitrogen Co.
The complete RMPI-1640 medium used for immunological2 Evidence-Based Complementary and Alternative Medicine
95% ethanol under reﬂux to remove
hydrophobic compounds
Treatment with Sevag reagent to
remove protein
Crude polysaccharide (BIW)
Dissolved in water (10%), freeze-thawing
Supernatant (BIWS) Precipitate (BIWP)
Sephadex G-75
BIWP1 BIWP2
Gradient ethanol precipitation
BIWS-1
(yield: 15%)
BIWS-2
(yield: 2.6%)
BIWS-3
(yield: 29%)
BIWS-4
(yield: 31%)
Sephadex G-75
High-Mw fraction
(BIWS-4a, 11% yield)
Low-Mw fraction
(BIWS-4b, 72% yield)
30% ethanol 50% ethanol 70% ethanol 90% ethanol
Fruit bodies of Bulgaria inquinans (Fries)
Hot water extraction (95 ◦C, 6h ×3),
80% ethanol precipitation
Figure 1: Extraction and puriﬁcation procedure of BIWS-4b.
testing had a pH of 7.4 and was supplemented with penicillin
(100IUmL−1), streptomycin (100μgml −1) and 10% fetal
bovine serum (FBS). All other reagents were of analytical
grade and made in China.
2.2. Animals. An equal number of male and female ICR
mice (Grade II, 6–8 weeks old), weighing 18–22g, were
purchased from the Pharmacology Experimental Center of
Jilin University (approval number: SCXK (Jilin) 2002-0002,
Changchun, China) and acclimatized for one week prior
to use. All mice were housed under standard conditions at
24±1◦Cwithhumidityof50±10%anda12/12hlight/dark
cycle. Rodent laboratory chow pellets and tap water were
supplied ad libitum. All procedures were in strict accordance
withPRChina legislation andwiththeguidelinesestablished
by the School of Life Sciences of Northeast Normal Univer-
sity regarding the use and care of laboratory animals. The
protocol was approved by the University’s Committee for
Animal Experiments and Science & Technology Department
of Jilin Province (approval number: SCXK (Jilin) 2003-
0001).
2.3. Isolation and Puriﬁcation of BIWS-4b. The isolation of
polysaccharides from fruit bodies of B. inquinans (Fries)
was carried out as previously described by our group [12].
In brief, dried fruit bodies of B. inquinans (Fries) were
extracted with 95% ethanol under reﬂux for 12h to remove
hydrophobic compounds and then extracted three times
with hot distilled water (6h for each extraction, 90–95◦C,
1:20w/v). The extracts were combined and concentrated
to one-tenth of the original volume, and then ethanol
was added to the concentrated extracts up to 80% to
precipitate the crude polysaccharides. Crude polysaccharides
were collected by centrifugation, and then treated with
Sevag reagent [13] to remove free proteins to give the
polysaccharidefraction(BIW).TheaqueoussolutionofBIW
(10% w/v) was frozen at –20◦C and then allowed to thaw
slowly at 4◦C, which yielded the soluble fraction (BIWS)
and insoluble fraction (BIWP). BIWP was fractionated and
characterized in our previous study [12]. In the present
study, BIWS was dissolved in water (10%w/v), and then
fractionated by gradient precipitation in 30, 50, 70 and
90% ethanol resulting in four fractions BIWS-1, BIWS-
2, BIWS-3 and BIWS-4, respectively. BIWS-4 was further
fractionated on a column (100×1.5cm) of Sephadex G-75
and eluted with 0.15M NaCl to give two fractions: BIWS-4a
collectedinthevoidvolumeandBIWS-4bcollectedasamain
portion. After dialysis in tubing (Mw cut-oﬀ 3.5×103 Da
for global protein), the fractions were concentrated and
lyophilized to give the pure polysaccharide fraction BIWS-
4b. The extraction and puriﬁcation procedure was shown in
Figure 1. All gel ﬁltration chromatographies were monitored
by assaying carbohydrate content.Evidence-Based Complementary and Alternative Medicine 3
2.4. Analytical Methods. The total carbohydrate content was
determined by the phenol-H2SO4 method using glucose
as a standard [14]. Protein content was determined in a
Bradford assay using bovine serum albumin as the standard
[15]. Contaminant endotoxin was analyzed in a limulus
amebocyte lysate (LAL) assay using an E-TOXATE kit
(Sigma, St. Louis, USA) according to the manufacturer’s
instructions.
Monosaccharide analysis was performed as described by
Hondaetal.[16].Brieﬂy,sample(2mg)washydrolyzedwith
2MCF 3COOH (1.0ml) at 120◦C for 3h. The hydrolyzed-
products (monosaccharides) were derivatized with 0.5M 1-
phenyl-3-methyl-5- pyrazolone (PMP) and 0.3M NaOH.
After neutralization with 0.3M HCl, the PMP-derivatives
were analyzed in a Shimadzu 10Avp HPLC system equipped
with a Shim-pak VP-ODS column (150 × 4.6mm i.d.)
with guard column and monitored by UV absorbance at
245nm.
The speciﬁc rotation was measured at 20±1◦Cw i t h
an automatic polarimeter (Model WZZ-2B, China). UV-Vis
absorbancespectrawererecordedwithaUV-Visspectropho-
tometer(ModelSP-754,China).FT-IRspectrawereobtained
on a Nicolet 560 FT-IR spectrometer with DTGS detector in
a range of 400–4000cm−1. The samples were ground with
KBr powder and then pressed into 1mm pellets for FT-IR
measurements.
The 13C NMR spectrum was recorded using a Bruker
5mm Broadband Observe probe at 20◦Ci naB r u k e rA v a n c e
600MHz spectrometer (Germany) operating at 150MHz.
Sample (20mg) was dissolved in D2O (99.8%, 0.5ml),
freeze-dried, redissolved in D2O( 0 . 5m l )a n dc e n t r i f u g e dt o
remove excess sample. The experiment was recorded using
standard Bruker software.
2.5. Homogeneity and Molecular Weight Determination.
Homogeneity and molecular weight were determined in
a Shimadzu 10Avp HPLC system equipped with a 10Avp
Pump and RID-10A Refractive Index Detector. The system
was linked to the gel ﬁltration column TSK-G3000PWXL
and sample was eluted with 0.2M NaCl at a ﬂow rate of
0.55mlmin−1 at 35.0±0.1◦C. The column was calibrated
by standard dextrans (50, 25, 12, 5 and 1kDa) using
linear regression. Sample concentration upon injection was
5mgml −1 and approximately 20μl was injected.
2.6. Methylation Analysis. The methylation analysis was
carried out according to the method of Needs and Sel-
vendran [17]. In brief, BIWS-4b (10mg) was dissolved in
DMSO (1.5ml) and then methylated by treatment with a
NaOH/DMSO suspension (1ml) and iodomethane (1ml).
T h em e t h y l a t e dp o l y s a c c h a r i d ew a se x t r a c t e dw i t hC H C l 3
and then the solvent was removed by vacuum evaporation.
The progress of methylation was followed by the disap-
pearance of the –OH band (3200–3400cm−1) in the FT-
IR spectrum. The per-O-methylated polysaccharides were
hydrolyzed subsequently by HCOOH (85%, 0.5ml) for 4h
and CF3COOH (2M, 1ml) for 6h at 100◦C. Partially methy-
lated sugars in the hydrolysate were reduced by NaBH4 and
then acetylated with pyridine (0.5ml) and acetic anhydride
(0.5ml) at 90◦C for 1h. The resulting mixture of alditol
acetates was analyzed by GC-MS. GC-MS was carried out
on an Agilent 6890N-5975 instrument equipped with a HP-5
column.
2.7. Preliminary Anti-Malaria Testing In Vivo
2.7.1. Parasite Inoculation. The Plasmodium yoelii strain
17XL was a gift from Prof. Cao Yaming (Department of
Immunology, China Medical University) and blood stage
parasites were stored in liquid nitrogen. The standard
inoculum consisted of 5×107 ml−1 P. yoelii parasitized ery-
throcytesfromadonormouse,whichwasusedtoinfectmice
intraperitoneally.
2.7.2. Suppressive Activity on Early Infection (4-Day Test).
Suppression of early infection was evaluated using a 4-
day test described by Peters and Robinson [18]. Brieﬂy,
after inoculating with 0.2ml of standard inoculum, the
mice were randomly divided into six groups of six mice
each. The polysaccharide-treated groups were given BIWS-
4b of diﬀerent dosages (50, 100 and 200mgkg−1), and
the co-treated group was given the mixture of BIWS-
4b (100mgkg−1) and artesunate (14mgkg−1). A negative
control group was administered physiological saline and
positive control groups were treated with artesunate at doses
of 14 or 28mgkg−1. The drugs were orally administered to
mice in 0.2ml doses daily for 4 consecutive days (Days 0–
3). On Day 4, blood smears were generated from tail blood
and stained with Giemsa stain. Drug activity was assessed
by evaluating the smears under a microscope. Parasitemia
(%) was calculated by dividing the number of parasitized
erythrocytes by the total number of erythrocytes. Average
chemosuppression (%) was calculated as 100 × [(A–B)/A],
where A is the average parasitemia of the negative con-
trol group and B is the average parasitemia of the test
group.
2.7.3. Prophylactic Activity on Residual Infection (Prophylactic
Test). Prophylactic activity was assessed according to the
method described by Peters [19]. Mice were randomly
divided into groups of six mice each and orally received
BIWS-4b or physiological saline (negative control) for 4,
6 ,8o r1 0c o n s e c u t i v ed a y sp r i o rt oi n f e c t i o n .T w e n t y - f o u r
hours after the ﬁnal administration of drug or saline, the
mice were inoculated with P. yoelii. Seventy-two hours after
inoculation, parasitemia levels were assessed in blood smears
from tail blood of each mouse, and parasitemia (%) and
average chemosuppression (%) were calculated.
2.8. Evaluation of Immunostimulating Activity In Vivo
2.8.1. Drug Administration. The mice were randomly
divided into groups of six mice each: a control group
(administered physiological saline) and 100 and 200mgkg−1
BIWS-4b groups. The drugs were given orally in doses of4 Evidence-Based Complementary and Alternative Medicine
0.2ml for 4, 6, 8 or 10 consecutive days. Twenty-four hours
after the ﬁnal administration of drug or saline, mice in the
malaria-bearing groups were inoculated with P. yoelii while
the control group was used to assess the macrophage phago-
cytosis and lymphocyte proliferation activities of BIWS-
4b in normal mice. Seventy-two hours after inoculation,
the macrophage phagocytosis and lymphocyte proliferation
activities of BIWS-4b in malaria-bearing mice were evalu-
ated.
2.8.2. Phagocytosis of Macrophage Assay. Chicken red blood
cells (CRBC) were used to assess macrophage phagocytosis
as described by Yang et al. [20]. Brieﬂy, on the last day,
1ml of 20% (v/v) CRBC was intraperitoneally injected into
each mouse, and the mice were sacriﬁced 30min later.
Physiological saline (2ml) was injected into the abdominal
cavity, and then 1ml ﬂuid was collected to make a smear
from each mouse. After incubating at 37◦Cf o r3 0m i ni na
humidiﬁed 5% CO2 incubator, the smears were centrifuged
to remove the supernatant, and the macrophages were ﬁxed
with methanol and stained by Giemsa-Wright for 7–10min.
The phagocytosis index was measured by counting the
number of phagocytosed CRBC per every 100 macrophage
cells, and the phagocytosis rate was measured by counting
the number of macrophages containing CRBC per every 100
macrophage cells.
2.8.3. Lymphocyte Proliferation Assay. Spleens were asepti-
cally extirpated from the immunized mice. Spleen single
cell suspensions were pooled in ice-cold Hank’s solution by
ﬁltering through sieve mesh. Spleen cells were depleted of
erythrocytes in Tris2NH4Cl (0.16M, Tris2NH4Cl, pH 7.2),
due to low-osmosis, followed by two washes in Hank’s
solution and resuspending in complete RPMI 1640 medium.
Splenocyte activity was measured above 95% as assessed by
the trypan blue dye exclusion method.
The lymphocyte proliferation assay was followed as
described by Lee et al. [21] with slight modiﬁcation.
Brieﬂy, spleen lymphocytes were seeded into 96-well ﬂat-
bottom microtiter plates at 5×106 cellsml−1 and cultured
in RPMI 1640 medium contained ConA (5.0μgml −1)o r
LPS (10.0μgml −1). The plates were incubated at 37◦Ci na
humidiﬁed atmosphere with 5% CO2. After 44h, 20μlo f
MTT solution (5μgml −1) was added to each well and the
cells were incubated for an additional 4h. After aspirating
the supernatant from the wells, 100μlo fD M S Ow a sa d d e d
to dissolve formazan crystal. The absorbance at 570nm was
measured using a Bio-Rad microplate reader (Model 550,
USA).
2.9. Statistical Analysis. All data were expressed as the
mean ± SD of six replicates and examined for statistical
signiﬁcance with Student’s t-tests. A result is considered
statistically signiﬁcant when P<. 05. One-way ANOVA
was conducted to assess signiﬁcant diﬀerences among the
treatments as a whole in order to avoid the error inherent
in performing multiple t-tests.
3. Results
3.1. Isolation and Puriﬁcation of BIWS-4b. Fruit bodies
of B. inquinans (Fries) were treated with hot water, and
extracted polysaccharides were precipitated in ethanol.
Deproteination by the Sevag method gave an 8% yield of
the polysaccharide (BIW) from dried fruit bodies. BIW was
composed of glucose, mannose and galactose in a molar
ratio of 1.0:1.3 :1.0, respectively. A freeze-thaw cycle of the
polysaccharide resulted in two fractions: BIWP (precipitate,
19%) and BIWS (supernatant, 63%). Analysis of BIWP
revealed glucan, which was further puriﬁed by Sephadex G-
75 gel ﬁltration chromatography to give a homogeneous β-
(1→6)-d-glucan [12].
BIWS consists of glucose, mannose and galactose in
a molar ratio of 1: 1:1 and exhibits a wide molecular
weight distribution from 15 to 50kDa. It was fractionated
by gradient precipitation in 30, 50, 70 and 90% ethanol,
whichresultedinthefractionsBIWS-1,BIWS-2,BIWS-3and
BIWS-4, respectively. BIWS-1, BIWS-2 and BIWS-3 showed
wide distributions on Sepharose CL-6B or Sephadex G-75
elution proﬁles, while BIWS-4 gave two relatively narrow
peaks on Sephadex G-75. Hence, BIWS-4 was fractionated
on a Sephadex G-75 column (1.5 × 100cm) into two
populations: BIWS-4a collected in the void elution volume
(11% yield) and BIWS-4b (72% yield) collected in the
eﬀective fractionation range as a main portion. BIWS-4a is
composedofglucose,mannoseandgalactoseinamolarratio
of 5.7:1.0:8.0. Because of its low yield and wide molecular
weight distribution, BIWS-4a was not studied further.
3.2. Analyses of BIWS-4b. BIWS-4b is a light brown powder
and its total carbohydrate content was determined to be 96%
by the phenol-H2SO4 method. The UV spectrum of BIWS-
4b contained no peaks at 260 or 280nm, and the Bradford
assay was negative, which indicated that BIWS-4b did not
contain protein and nucleic acid. A limulus amebocyte
lysate (LAL) assay revealed less than 0.015EU (endotoxin
units) mg−1, which indicates a negative result. Analysis of
sugar content showed that BIWS-4b consists of mannose
(27.2%), glucose (15.5%) and galactose (57.3%). BIWS-4b
gives a narrow symmetric peak by HPSEC (Figure 2), and its
molecularweightwasestimatedtobe7.4kDa(polydispersity
index, Mw/Mn:1.35), which suggests that BIWS-4b is a
homogenous polysaccharide fraction.
The speciﬁc rotation measurement of BIWS-4b is [α]D20
–51.9◦ (c 0.2, H2O). The high negative rotation suggests
the dominating presence of β-glycosidic linkages. The FT-
IR spectrum of BIWS-4b (Figure 3) shows absorption of β-
type glycosidic linkages at 875.5cm−1. The other absorp-
tion bands at 3392.2cm−1 (hydroxyl stretching vibration),
2933.3cm−1 (C–H stretching vibration), and 1647.0cm−1
(bound water) were from the corresponding sugar residues.
Methylation products were sequentially acetylated and
reduced to give seven methylated alditol acetates (Figure 4).
This procedure revealed that galactosyl residues were (1→
6)-linked, (1→5)-linked and (1→5,6)-linked Galf units;
glucosyl residues were (1→4)-linked and non-reducing
terminal Glcp units; mannosyl residues were (1→2)-linked,Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: HPSEC elution proﬁle of BIWS-4b.
(1→6)-linked, (1→2,6)-linked and non-reducing terminal
Manp units. The ratios of each residue are listed in Table 1.
ThestructuralfeaturesofBIWS-4bwerefurtheranalyzed
by 13C NMR; assignments of carbon atom signals are listed
in Table 2 and Figure 5. According to NMR data in the
literatures [22–28], the anomeric carbon signals at δ 107.73,
107.03 and 106.92 can be attributed to C-1 of three diﬀerent
linkages of β-Galf residues; δ 102.43 and 102.19 correspond
to C-1 of β-Glcp and δ ∼ 101.19 to 97.24 correspond
to C-1 of α-Manp. These results were consistent with
those of methylation analysis. Combining the results from
methylation and NMR analyses, we deduced that BIWS-4b
was mainly composed of (1→6)-linked, (1→5)-linked, and
(1→5,6)-linked β-Galf units, as well as (1→4)-linked, non-
reducing terminal β-Glcp units, and (1→2)-linked, (1→6)-
linked, (1→2,6)-linked and non-reducing terminal α-Manp
units.
3.3. Anti-Malarial Activity of BIWS-4b
3.3.1. Anti-Malarial Activity of BIWS-4b on Early Infection.
The anti-malarial activity of BIWS-4b was tested in mice
by the 4-day method. As shown in Figure 6, parasitemia of
BIWS-4b treated groups was signiﬁcantly down (P< .05
or P< .01), in a dose-dependent manner, compared with
the control group. Correspondingly, chemosuppression was
signiﬁcantly elevated. Chemosuppression was up 27.84% in
miceadministeredoraldosesof100mgkg−1 day−1 compared
to controls. Artesunate is an eﬀective anti-malarial drug
used in the current market. Artesunate-induced chemo-
suppression was 58.59% at a dose of 14mgkg−1 day−1.
Co-administration of BIWS-4b and artesunate resulted in
89.85% chemosuppression, which is higher than the sum
of the suppression caused by BIWS-4b and artesunate
Wavenumbers (cm−1)
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3392.23
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Figure 3: FT-IR spectra: (a) BIWS-4b and (b) partially methylated
BIWS-4b.
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Figure 4: GC proﬁle of BIWS-4b in methylation analysis.
individually, indicating that BIWS-4b and artesunate acted
synergistically.
3.3.2.Anti-MalarialActivityofBIWS-4bonResidualInfection.
T h ep r o t e c t i v ee ﬀect of BIWS-4b against malarial infection
was examined by a residual infection assay in mice. The
polysaccharides were administrated to mice followed by
inoculation with P. yoelii. Our results indicate that BIWS-
4b signiﬁcantly decreased infection by P. yoelii (Figure 7(a)),
which suggests that BIWS-4b enhanced the protective ability
of mice against malaria. The protective ability increased
with the time of administration, peaking on the eighth day.
BIWS-4b signiﬁcantly increased chemosuppression in the
dose range of 25–500mgkg−1 compared with the control
group(P<. 05orP<. 01)(Figure 7(b));thedataformabell-
shaped curve. At a dose of 100mgkg−1, chemosuppression
reached its highest level of 46.21% on the eighth day.6 Evidence-Based Complementary and Alternative Medicine
Table 1: Methylation analysis of BIWS-4b.
Partially methylated glycitol Molar ratioa Retention time (min) Linkage type
1,4,5-Tri-acetyl-2,3,6-tri-O-methyl galactitol 4.6 17.95 →5)-Galf-(1→
1,4,5,6-Tetra-acetyl-2,3-di-O-methyl galactitol 3.1 17.88 →5,6)-Galf-(1→
1,4,6-Tri-acetyl-2,3,5-tri-O-methyl galactitol 7.6 18.94 →6)-Galf-(1→
1,4,5-Tri-acetyl-2,3,6-tri-O-methyl glucitol 2.2 18.32 →4)-Glcp-(1→
1,5-Di-acetyl-2,3,4,6-tetra-O-methyl glucitol 2.6 17.11 Glcp-(1→
1,2,5-Tri-acetyl-3,4,6-tri-O-methyl mannitol 2.4 17.84 →2)-Manp-(1→
1,5-Tri-acetyl-2,3,4,6-tri-O-methyl mannitol 1.0 17.06 Manp-(1→
1,2,5,6-Tetra-acetyl-3,4-di-O-methyl mannitol 1.2 18.82 →2,6)-Manp-(1→
1,5,6-Tri-acetyl-2,3,4-tri-O-methyl mannitol 2.9 18.72 →6)-Manp-(1→
aRelative molar ratio, calculated from the ratio of peak area.
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Figure 5: 13C NMR spectrum of BIWS-4b. Solvent: D2O, temperature: 20◦C.
Table 2: 13C NMR chemical shifts of BIWS-4b in D2O.
Residue δ (ppm)
C-1 C-2 C-3 C-4 C-5 C-6
→5)-β-Galf-(1→ 107.73 80.93 76.81 81.18 75.47 62.73
→5,6)-β-Galf-(1→ 107.03 81.45 76.40 82.50 74.20 68.01
→6)-β-Galf-(1→ 106.92 82.00 76.65 83.98 69.89 69.70
→4)-β-Glcp-(1→ 102.43 73.18 74.30 79.09 74.83 60.64
β-Glcp-(1→ 102.19 72.96 74.20 69.12 75.83 60.32
α-Manp-(1→ 101.19 69.12 69.54 66.56 72.40 60.10
→2)-α-Manp-(1→ 99.45 77.25 68.76 66.67 72.40 60.10
→6)-α-Manp-(1→ 98.37 69.12 69.54 66.58 71.95 64.89
→2,6)-α-Manp-(1→ 97.24 77.62 69.40 66.67 71.95 64.92
3.4. Immunological Activity of BIWS-4b
3.4.1.EﬀectonMacrophagePhagocytosis. TheeﬀectofBIWS-
4b on macrophage phagocytosis was determined using
chicken red blood cells (CRBC) in malaria-bearing mice and
normal mice. As shown in Figure 8, the phagocytic rate and
the phagocytic index were signiﬁcantly increased compared
with the control group by BIWS-4b treatment at doses of
100 and 200mgkg−1 (P< .01). At a dose of 100mgkg−1
BIWS-4b, macrophage phagocytosis was enhanced to a
greater extent than at a dose of 200mgkg−1, and the former
dose caused the most macrophage phagocytosis in malaria-
bearingmiceandnormalmiceattheeighthday.Theseresults
are consistent with residual infection.
3.4.2. Eﬀect on Lymphocyte Proliferation. Splenic lymphocyte
proliferation is usually followed to evaluate a general eﬀect
on immune cells. Lymphocyte proliferation induced by
ConA reﬂects T-lymphocyte activity while proliferation
induced by LPS reﬂects B-lymphocyte activity. The eﬀects
of BIWS-4b on ConA- and LPS-induced lymphocyte prolif-
eration were tested in vivo by the MTT method. As shown
in Figure 9, in the presence of ConA or LPS, BIWS-4b
signiﬁcantly increased lymphocyte proliferation in malaria-
bearing or normal mice compared to the control group
(P< .05). These results indicate that BIWS-4b was ableEvidence-Based Complementary and Alternative Medicine 7
Control A14 B50 B100 B200 A14 + B100
∗
∗∗
∗∗
∗∗
∗∗
0
5
10
15
20
25
30
35
40
P
a
r
a
s
i
t
e
m
i
a
(
%
)
Figure 6: Anti-malarial eﬀect of BIWS-4b on early infection. After
inoculating with P. yoelii, the mice were orally treated with A:
artesunate (14mgkg−1), B: BIWS-4b (50, 100 and 200mgkg−1),
or combination of A and B for four consecutive days. Twenty-four
hours after the ﬁnal administration of drug or saline, parasitemia
(%) was assessed in blood smears from tail blood of each mouse.
Each value represents the mean±S.D. The signiﬁcant values are
indicated by ∗P<.05 and ∗∗P< .01.
to activate both T and B cells. At a dose of 100mgkg−1,
BIWS-4b induced higher eﬀect on lymphocyte proliferation
than that at a dose of 200mgkg−1 and, similar to its
eﬀect on macrophage phagocytosis, lymphocyte prolifera-
tion both in malaria-bearing mice and normal mice peaked
at the eighth day. Taken together, the data suggest that
BIWS-4b can stimulate T/B-cells to suppress the spread of
malaria.
4. Discussion
Polysaccharides from fungi often possess immunological
activities that can protect the body from microbial and
parasitic attack [29–31]. Although some polysaccharides
from ascomycetous lichens are reported to be composed
of galactofuranose, glucopyranose and mannopyranose
residues [25, 27, 28, 32–37], little work about possible anti-
malarial activity has been performed. Lentinan (1,3-β-d-
glucan) has recently been investigated for its anti-malarial
activity using the P. yoelii blood-stage infection model and
found to possess prophylactic potential for the treatment
of malaria via immunostimulation [9]. In this article, we
isolated, for the ﬁrst time, a heteropolysaccharide fraction
(BIWS-4b) containing α-d-Manp, β-d-Glcp and β-d-Galf
from the non-lichenized edible mushroom B. inquinans
(Fries). Considering the complex structure of BIWS-4b,
we supposed it may have potential biological activities.
Therefore, BIWS-4b was evaluated for its complementary
therapy and prophylactic activities against malaria as well
as its immunostimulating activity. The results indicated that
BIWS-4b had markedly suppressive activity on early or
residual infection. Thus, it is possible that BIWS-4b could
be used as a complementary drug or protective agent against
malaria.
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Figure 7: Anti-malarial eﬀect of BIWS-4b on residual infection: (a)
the mice were given BIWS-4b at 100mgkg−1 and 200mgkg−1 for 4,
6, 8, or 10 consecutive days; (b) the mice were given BIWS-4b at 25,
50, 100, 200, 400 and 500mgkg−1 for 8 consecutive days. Twenty-
four hours after the ﬁnal administration of drug or saline, the mice
were inoculated with P. yoelii. Seventy-two hours after inoculation,
parasitemia (%) was assessed in blood smears from tail blood of
each mouse. Each value represents the mean±S.D. The signiﬁcant
values are indicated by ∗P< .05 and ∗∗P< .01.
Artesunate is an eﬀective drug currently used to cure
malarial infection. The endoperoxide moiety of its molecular
structure can oxidize parasitic membranes and react with
heme to form a cytotoxic carbon-centered radical inter-
mediate that further reacts with susceptible groups within
parasite enzymes and lipids [38–40]. However, artesunate
h a ss o m en e g a t i v es i d ee ﬀects including interfering with
some aspects of the host immune system, resulting in the
diﬃculty of establishing a long-lasting protective immunity
against malaria [41]. Therefore, artesunate-based combi-
nation therapy was recommended by the World Health8 Evidence-Based Complementary and Alternative Medicine
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Figure 8: Eﬀect of BIWS-4b on macrophage phagocytosis in normal mice and malaria-bearing mice: (a) phagocytosis rate in normal mice,
(b) phagocytosis index in normal mice, (c) phagocytosis rate in malaria-bearing mice, (d) phagocytosis index in malaria-bearing mice. Each
value represents the mean±SD. Signiﬁcant diﬀerences from the negative control were evaluated using student’s t-test: ∗P< .05, ∗∗P<.01.
Organization (WHO) as a new prospective paradigm [42].
Lymphocytes are the key eﬀecter cells of the mammalian
immune system and stimulating macrophages is another
way to enhance immunological activity [43, 44]. BIWS-4b
signiﬁcantlyenhancedspleenlymphocyteproliferationupon
stimulation by ConA or LPS and augmented macrophage
phagocytosis in malarial-bearing or normal mice. In our
experiments, it was observed that both immunological
enhancement of BIWS-4b and its protection against malarial
infection peaked at 100mgkg−1 on Day 8, which implied
that its anti-malarial activity might be intermediated by
enhancing host immune competence. In combination with
artesunate, BIWS-4b was able to recover immune system
functionality that was previously suppressed by artesunate
in mice. The synergistic eﬀect of BIWS-4b and artesunate
maybeutilizedtoenhanceandrestoreartesunate-suppressed
immune function. Similar results were observed for lentinan
[9].
The prophylactic activity against malaria and the
immunological enhancement of BIWS-4b exhibited a bell-
shaped curve. One interpretation of this eﬀect is that
signal transduction mechanisms underlying the action of
lymphocytes and macrophages might be regulated down-
ward by exposure to a higher dosage of BIWS-4b [45].
An alternative interpretation is that BIWS-4b has not only
eﬀects which promote the immune system, but also those
which inhibit their system, and the promoting mechanisms
might be masked by its inhibitory eﬀects at a higherEvidence-Based Complementary and Alternative Medicine 9
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Figure 9: Eﬀect of BIWS-4b on lymphocyte proliferation in normal mice and malaria-bearing mice: (a) ConA-induced T-lymphocyte
proliferation in normal mice, (b) LPS-induced B-lymphocyte proliferation in normal mice; (c) ConA-induced T-lymphocyte proliferation
in malaria-bearing mice; (d) LPS-induced B-lymphocyte proliferation in malaria-bearing mice. Each value represents the mean±SD.
Signiﬁcant diﬀerences from the negative control were evaluated using Student’s t-test: ∗P<.05, ∗∗P<.01.
dosage [46]. Similar results have been observed in some
polysaccharides when used as complementary drugs for
anti-cancer treatments [47–50], such as the tumor growth
inhibition of a Cordyceps sinensis polysaccharide [47]a n d
the TNF-α level increase by an Aloe vera polysaccharide
[48].
In conclusion, a water-soluble heteropolysaccharide
BIWS-4b was puriﬁed from fruit bodies of B. inquinans
(Fries). It was found to contain (1→6)-, (1→5)- and (1→
5,6)-linked β-Galf units, as well as (1→4)-linked non-
reducing terminal β-Glcp units, and (1→2)-linked, (1→6)-
linked, (1→2,6)-linked and non-reducing terminal α-Manp
units. BIWS-4b was shown to possess marked suppressive
activity against early infection of malaria by the 4-day
method in mice. Residual infection and immunological
assays indicated that BIWS-4b had signiﬁcant prophylactic
activity against malaria by stimulating the immune sys-
tem. Moreover, BIWS-4b increased anti-malarial activity
of artesunate at early infection by oral administration in
combination. The deduced anti-malarial action of BIWS-
4b was shown in Figure 10. Therefore, BIWS-4b could be
considered a potential adjuvant of anti-malarial drugs.10 Evidence-Based Complementary and Alternative Medicine
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Figure 10: The deduced anti-malarial action of BIWS-4b: when infected with malaria, the host generates a protective immune response,
including cellular and humoral immunity. BIWS-4b can signiﬁcantly enhance the immune competence of the host and exhibits remarkable
prophylactic activity against malaria. In combination with artesunate, BIWS-4b can restore the artesunate-suppressed immune function and
enhance the anti-malarial activity of artesunate.
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